Qiagen's stock plummets 10% as pandemic gains vanish amid weak demand
Qiagen N.V. has faced a sharp decline in its stock price this week. Shares dropped by more than 10% on Tuesday, wiping out gains made during the pandemic. The company’s struggles come amid falling demand for a key tuberculosis test and broader market challenges. The steep sell-off began on Tuesday, with shares plunging 10.7%. The losses continued on Wednesday, adding another 1.2% drop. Year-to-date, the stock has now fallen by 30.8%, returning to levels last seen in November 2019.
Qiagen recently cut its full-year guidance after reporting a mixed first quarter. Analysts point to several headwinds, including weaker U.S. sales, declining demand for its tuberculosis test, and ongoing geopolitical uncertainty. Despite the downturn, the company’s forward price-to-earnings ratio stands at 15.
Financial firms have adjusted their outlooks. DZ Bank lowered its price target from €50 to €38 but kept a 'Buy' rating. Jefferies, however, maintained a more optimistic stance, retaining a 'Buy' rating with a €59 target. The next key support level for the stock is now seen at €27.70. The recent stock decline has erased Qiagen’s pandemic-era gains, leaving investors cautious. With revised guidance and persistent market pressures, the company faces a challenging road ahead. Analysts remain divided on its future performance, though some still see long-term value.
